Non-alcoholic steatohepatitis (NASH) is a severe and potentially life-threatening form of non-alcoholic fatty liver disease (NAFLD) that has emerged as a major health and societal burden in the United States. Of the estimated one in four individuals who have NAFLD, one in five has NASH, and although the pathogenesis of NAFLD and NASH have not been fully elucidated, it is a result of several pathways that may lead to advanced fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and death.
This CME Outfitters enduring material features a renowned panel of experts highlighting the underlying mechanisms of NASH via innovative augmented reality (AR) animations and presenting real-world case scenarios to share clinical insights on how to choose appropriate non-invasive diagnostic modalities, as well as translate latest data on emerging targeted therapies and their implications for clinical practice.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from Intercept Pharmaceuticals, Inc.
Gastroenterologists, PAs, nurse practitioners, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Noureddin reports that he receives research support from Allergan; Bristol-Myers Squibb Company; Conatus Pharmaceuticals Inc.; Enanta Pharmaceuticals, Inc.; Galectin Therapeutics Inc.; Galmed Pharmaceuticals; GENFIT; Gilead Sciences, Inc.; Novartis; Shire; and Zydus Pharmaceuticals, Inc. He is on the advisory board or speakers bureau for Abbott; Allergan; Blade Therapeutics; EchosensTM North America; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novartis; OWL; Pfizer Inc.; Roche Diagnostics, North America; and Siemens. He is a stock shareholder (directly purchased) of Ananetos; and Viking Therapeutics, Inc.
Dr. Loomba reports that his institution has received grant support from Allergan; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Cirius Therapeutics; Eli Lilly and Company; Galectin Therapeutics Inc.; Galmed Pharmaceuticals Ltd.; GE Healthcare Life Sciences; Genfit; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; GRAIL, Inc.; Janssen Pharmaceuticals, Inc.; Madrigal Pharmaceuticals, Inc.; Merck & Co., Inc.; NGM Biopharmaceuticals; NuSirt Biopharma; Pfizer Inc.; pH Pharma Co., Ltd.; Prometheus Laboratories Inc.; and Siemens. He is a consultant or advisory board member for Alnylam Pharmaceuticals,Inc./Regeneron Pharmaceuticals Inc.; Arrowhead Pharmaceuticals, Inc.; AstraZeneca; Bird Rock Bio; Boehringer Inghelheim; Bristol-Myer Squibb Company; Celgene Corporation; Cirius Therapeutics; CohBar, Inc.; Conatus Pharmaceuticals Inc.; Eli Lilly and Company; Galmed Pharmaceuticals Ltd.; Gemphire Therapeutics Inc.; Gilead Sciences, Inc.; Glimpse Bio; GNI Group Ltd.; GRI Bio; Inipharm, Inc.; Intercept Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Metacrine, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; Prometheus Laboratories Inc.; Promethera? Biosciences; Sanofi-Aventis U.S. LLC; Siemens; and Viking Therapeutics, Inc. He receives other financial or material support as the co-founder of Liponexus, Inc.
Dr. Younossi reports that he receives research support from Bristol-Myers Squibb Company; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.; Merck & Co., Inc.; and Siemens. He is a consultant for Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novo Nordisk; Siemens; and Terns Pharmaceuticals, Inc.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-150-H01-P.
Call us at 877.CME.PROS (877.263.7767).